Johnson & Johnson (NYSE:JNJ) on Wednesday reported a second-quarter 2025 adjusted earnings of $2.77 per share, down 1.8% year ...

Now, after setting an innovative medicines sales record in the year’s second quarter, it appears J&J’s confidence was well placed.

Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2025. "Today’s strong results reflect the depth and strength of Johnson & Johnson’s uniquely diversified business operating ...